Sea Moss and EGPA: Safety Notes

Sea Moss for Eosinophilic Granulomatosis with Polyangiitis (EGPA Churg-Strauss MPO-ANCA Asthma Eosinophilia)

A deep, science-grounded look at how the trace minerals, marine polysaccharides and omega-3 fatty acids in sea moss intersect with the eosinophil biology, ANCA-associated vasculitis pathways and Th2 immune signaling that define EGPA.

Sea moss delivers minerals and trace elements your body uses every day — including selenium, zinc and iodine that play documented roles in immune regulation and antioxidant defense.

IL-5 & Eosinophil Biology MPO-ANCA Vasculitis Th2 Immune Axis Fucoidan · Selenium · Omega-3

Eosinophilic Granulomatosis with Polyangiitis (EGPA) — historically known as Churg-Strauss Syndrome — is a rare ANCA-associated small-vessel vasculitis built on three overlapping pillars: severe adult-onset asthma, dramatic blood and tissue eosinophilia, and necrotizing granulomatous inflammation. This page explores the disease biology in depth and then examines, transparently and without overpromising, where the nutrients concentrated in sea moss touch the same inflammatory and antioxidant pathways. Nothing here is a treatment for EGPA — but understanding the overlap helps you make informed nutrition decisions alongside your rheumatologist.

Understanding EGPA: The Three-Pillar ANCA-Associated Vasculitis

EGPA sits within the family of ANCA-associated vasculitides (AAV) alongside granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). What makes EGPA distinct is its eosinophilic personality — it is as much an eosinophilic disease as it is a vasculitis. Clinically and pathologically, EGPA is defined by a triad:

Asthma (the hallmark, present in 95–100% of patients): Typically severe, adult-onset, late-developing asthma that is often difficult to control and frequently precedes the vasculitic phase by several years. The asthma is the prodrome — the canary in the coal mine — and its eosinophilic, corticosteroid-dependent character distinguishes it from ordinary allergic asthma.
Blood eosinophilia (>10% of white cells or an absolute count >1.5×10⁹/L): Often markedly elevated, sometimes exceeding 5×10⁹/L. The degree of eosinophilia tracks disease activity and tissue damage, since eosinophils themselves are the primary effectors of injury.
Extravascular granulomas and eosinophilic tissue infiltration: Necrotizing granulomas rich in eosinophils, along with eosinophil-laden infiltrates of the lungs, heart, gut, nerves and skin.

EGPA classically evolves through three phases: a prodromal/allergic phase (asthma, rhinitis, nasal polyps, sinusitis), an eosinophilic phase (peripheral eosinophilia and tissue infiltration resembling Loeffler's syndrome or eosinophilic pneumonia/gastroenteritis), and a vasculitic phase (necrotizing small-vessel vasculitis with mononeuritis multiplex, purpura and potentially life-threatening organ involvement).

The ACR/EULAR 2022 Classification Criteria

The 2022 American College of Rheumatology / European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for EGPA assign weighted points to clinical and laboratory features once a diagnosis of small- or medium-vessel vasculitis has been established. Heavily weighted positive items include obstructive airway disease, nasal polyps and blood eosinophilia ≥1×10⁹/L, while features such as hematuria and a positive cytoplasmic-ANCA (c-ANCA / anti-PR3) pattern weigh against an EGPA classification. A cumulative score of ≥6 classifies the patient as EGPA. These criteria reflect how central eosinophilia and airway disease are to the EGPA identity.

The Molecular Engine: IL-5, Th2 Cytokines and Eosinophil Effectors

To understand where nutrition could plausibly intersect, it helps to map the cytokine circuitry that drives EGPA. The disease is fundamentally a type 2 (Th2) immune disorder layered onto a vasculitic process.

IL-5: The Master Eosinophil Cytokine

Interleukin-5 (IL-5) is the dominant cytokine of EGPA. Produced by Th2 lymphocytes and type 2 innate lymphoid cells (ILC2s), IL-5 controls eosinophil maturation in the bone marrow, mobilization into the blood, survival in tissues, and activation. The clinical confirmation of IL-5's central role came when mepolizumab — a monoclonal antibody against IL-5 — became the first FDA-approved targeted therapy for EGPA in 2017–2021, validated by the landmark MIRRA trial showing more weeks in remission and reduced glucocorticoid burden.

IL-4, IL-13 and Eotaxin-3

The broader Th2 milieu includes IL-4 and IL-13, which drive IgE class switching, mucus production and goblet-cell hyperplasia, and eotaxin-3 (CCL26), a powerful eosinophil chemoattractant that recruits eosinophils into tissues. Elevated eotaxin-3 is among the more specific biomarkers of active EGPA. This Th2 predominance explains the characteristic elevated total IgE seen in many patients.

The Vasculitic Layer: NF-κB, TNF-α and IL-6

Superimposed on the eosinophilic process is the vasculitic engine driven by the master inflammatory transcription factor NF-κB and its downstream cytokines TNF-α and IL-6. These mediators amplify endothelial activation, leukocyte adhesion and the necrotizing small-vessel inflammation that defines the vasculitic phase. In MPO-ANCA-positive patients, neutrophil activation by ANCA further fuels endothelial injury through NETosis and complement C5a amplification.

Eosinophil Granule Proteins: The Tissue-Damaging Weapons

When eosinophils degranulate, they release a cytotoxic arsenal directly responsible for tissue damage in EGPA:

Major Basic Protein (MBP): Highly cationic; damages epithelium, nerves and cardiac tissue, and is implicated in endomyocardial fibrosis.
Eosinophil Cationic Protein (ECP): A ribonuclease that is also a clinical biomarker of eosinophil activity and tracks disease severity.
Eosinophil Peroxidase (EPX/EPO): Catalyzes the production of hypobromous acid — a halogenating oxidant considerably more reactive than the hypochlorous acid generated by neutrophil myeloperoxidase, driving intense oxidative tissue injury.
Eosinophil-Derived Neurotoxin (EDN): A ribonuclease that contributes to the neural damage seen in mononeuritis multiplex.

The release of these proteins — especially EPX-derived oxidants — links EGPA tissue injury to oxidative stress, which is exactly where selenium-dependent antioxidant enzymes enter the conversation.

ANCA-Positive vs ANCA-Negative EGPA: Two Faces of One Disease

One of the most clinically important distinctions in EGPA is ANCA status. Roughly 40% of EGPA patients are ANCA-positive — almost always the MPO-ANCA (p-ANCA / anti-myeloperoxidase) pattern — while about 60% are ANCA-negative. These two subsets behave like overlapping but distinct phenotypes, with meaningful implications for organ risk and treatment.

MPO-ANCA-Positive EGPA (~40%)

A more classically vasculitic phenotype. ANCA-mediated neutrophil activation drives small-vessel necrotizing vasculitis, much like microscopic polyangiitis.

Higher rates of glomerulonephritis and renal involvement
Mononeuritis multiplex (foot drop, wrist drop) more frequent
Palpable purpura and biopsy-proven vasculitis
Alveolar hemorrhage in severe cases
Neutrophil NETosis and complement C5a amplification; HLA-DQ linked

ANCA-Negative EGPA (~60%)

A more eosinophilic, tissue-infiltrative phenotype. Damage is driven predominantly by eosinophil granule proteins rather than ANCA-neutrophil vasculitis.

Cardiac involvement markedly more common — and the leading cause of mortality
Eosinophilic pulmonary infiltrates and pneumonia
Eosinophilic gastroenteritis
Lower rate of renal disease
Damage mediated by MBP, ECP and EPX tissue infiltration

This dichotomy matters because the cardiac-predominant ANCA-negative subset carries the highest mortality, and antioxidant and pro-resolving nutrition strategies that counteract eosinophil-driven oxidative injury are most conceptually relevant precisely in this group.

⚠️ Cardiac EGPA: The Leading Cause of Mortality

Cardiac involvement is the single most dangerous feature of EGPA, responsible for roughly half of all EGPA-related deaths. It is most common in ANCA-negative, highly eosinophilic patients, where eosinophil granule proteins — particularly Major Basic Protein — directly damage the myocardium.

The cardiac manifestations include eosinophilic myocarditis, Loeffler's (eosinophilic) endocarditis with mural thrombus formation, pericarditis and pericardial effusion, and progression to endomyocardial fibrosis with restrictive cardiomyopathy and heart failure. The fibrosis is driven substantially by TGF-β1 signaling through the SMAD pathway. Because cardiac EGPA can be clinically silent until advanced, cardiac MRI and biomarkers (troponin, NT-proBNP) are used for surveillance.

The oxidative mechanism is central: eosinophil peroxidase generates reactive oxidant species in cardiac tissue, and MBP cytotoxicity drives fibrosis. This is the biological reason that selenium-dependent cardiac selenoproteins and antioxidant defense are of particular theoretical interest in this disease — though never as a substitute for the disease-modifying therapy this complication demands. Any cardiac symptoms in EGPA are a medical emergency requiring immediate specialist care.

Organ-by-Organ: How EGPA Presents

Respiratory

Beyond the defining asthma, EGPA produces fleeting (migratory) pulmonary infiltrates on imaging, eosinophilic pneumonia, and upper-airway disease including chronic rhinosinusitis and nasal polyposis. The sinus disease is so common it is part of the classification criteria.

Peripheral Nervous System

Mononeuritis multiplex — the asymmetric, painful damage to individual peripheral nerves producing classic foot drop and wrist drop — is one of the most characteristic vasculitic features, particularly in MPO-ANCA patients. It results from vasculitis of the vasa nervorum depriving individual nerves of blood, with eosinophil-derived neurotoxin contributing to the nerve injury.

Skin

Cutaneous disease appears as palpable purpura (especially on the lower limbs), subcutaneous nodules, urticaria, and eosinophilic infiltration of the dermis. Skin biopsy often shows leukocytoclastic vasculitis with eosinophils.

Gastrointestinal and Renal

Eosinophilic gastroenteritis can cause abdominal pain, diarrhea, bleeding and, rarely, bowel ischemia. Renal involvement (glomerulonephritis) is far more common in the ANCA-positive subset and is a key driver of the prognostic score below.

The Five-Factor Score (FFS) for Prognosis

The Five-Factor Score (FFS), revised in 2011, predicts mortality risk in EGPA. The five poor-prognosis factors are: age >65 years, cardiac insufficiency, gastrointestinal involvement, renal insufficiency (elevated creatinine), and the absence of ENT (ear-nose-throat) manifestations (paradoxically, ENT involvement is protective). A higher FFS guides more aggressive immunosuppression, particularly the use of cyclophosphamide.

Conventional Treatment of EGPA

EGPA management is the domain of rheumatology and is built on suppressing eosinophilic and vasculitic inflammation. Understanding it provides context for where nutrition can — and cannot — fit.

Therapy	Mechanism	Role in EGPA
Corticosteroids	Broad anti-inflammatory; suppress eosinophils and cytokines	Mainstay of induction; most patients respond dramatically. Long-term goal is steroid sparing.
Mepolizumab	Anti-IL-5 monoclonal antibody	First FDA-approved targeted EGPA therapy (MIRRA trial: 47% remission vs 18% placebo); reduces steroid dose.
Benralizumab	Anti-IL-5 receptor-α (IL-5Rα); depletes eosinophils via ADCC	Demonstrated non-inferiority to mepolizumab; potent eosinophil depletion.
Cyclophosphamide	Cytotoxic immunosuppressant	Reserved for severe, organ-threatening or ANCA-positive disease with renal/cardiac/neurologic involvement.
Azathioprine	Antimetabolite immunosuppressant	Maintenance therapy to sustain remission and spare steroids after induction.
Rituximab	Anti-CD20 B-cell depletion	Favored especially in refractory ANCA-positive, vasculitic-predominant EGPA.

These therapies are non-negotiable for active EGPA. A note of caution: aspirin and NSAIDs are often avoided in salicylate-sensitive asthmatics with EGPA, so any anti-inflammatory strategy should be physician-directed. The nutrition discussion that follows is about supporting the body's nutritional and antioxidant baseline — not replacing any of the above.

Where Sea Moss Enters the Picture

Sea moss (Chondrus crispus and Genus Gracilaria) is a red marine algae prized for its dense nutritional matrix — famously minerals and trace elements, plus marine polysaccharides like fucoidan and carrageenan, and small amounts of omega-3 fatty acids. Several of these nutrients touch the exact pathways described above: eosinophil cytokine signaling, NF-κB-driven vasculitis, oxidative stress from eosinophil peroxidase, and the resolution of type 2 inflammation. Below we examine each one honestly — as a nutritional supporter of normal immune and antioxidant function, not a therapy.

Nutrient Deep-Dive: Sea Moss Compounds and EGPA Biology

🌿 Fucoidan Marine Polysaccharide

Fucoidan is a sulfated polysaccharide found in many marine algae and a signature bioactive of sea moss. In laboratory and preclinical research, fucoidan has been studied as a modulator of NF-κB signaling — the same master transcription factor that drives TNF-α, IL-6 and the vasculitic inflammation of EGPA. By dampening NF-κB activation, fucoidan has shown anti-inflammatory effects on endothelial activation in experimental models.

Of particular relevance to eosinophilic disease, fucoidan has been investigated for its effects on IL-5 and IL-6 signaling and eosinophil recruitment in allergic airway models, where it reduced eosinophil infiltration, eotaxin-driven trafficking and Th2 cytokine output. Some research also points to fucoidan tempering the activity of eosinophil-associated mediators such as Major Basic Protein, and to anti-complement activity (interfering with C3, C4 and C5a generation) most relevant to the ANCA-positive subset. Fucoidan has additionally shown the ability to inhibit TGF-β1/SMAD fibrosis signaling in preclinical cardiac and serosal models — the same profibrotic axis that scars the endomyocardium. In the context of EGPA's intertwined eosinophilic and vasculitic biology, fucoidan is the sea moss component most conceptually aligned with the disease's core machinery — supporting the body's normal inflammatory balance.

🛡️ Selenium Antioxidant Trace Mineral

Selenium is arguably the most mechanistically interesting mineral for EGPA. It is the essential cofactor for the glutathione peroxidase (GPx) family of selenoenzymes that neutralize hydrogen peroxide and lipid peroxides — directly counteracting the halogenative oxidant burden created by eosinophil peroxidase (EPX) and its hypobromous acid. Eosinophils themselves express high levels of GPx4, the selenoprotein that protects membranes from lipid peroxidation, while the vasculature relies on GPx1 and GPx3 for systemic antioxidant defense.

This matters because much of EGPA's tissue injury — especially cardiac fibrosis — is driven by eosinophil-derived oxidants. Selenium also supports cardiac selenoproteins; severe selenium deficiency is independently associated with cardiomyopathy (Keshan disease), making adequate selenium status particularly relevant in a disease where cardiac involvement is the leading cause of death. Low selenium has also been observed in various eosinophilic and inflammatory disorders, hinting that chronic eosinophilic inflammation can deplete this trace mineral. Sea moss contributes bioavailable selenium (as selenomethionine) that supports normal antioxidant enzyme function and helps the body manage oxidative stress.

🐟 Omega-3 EPA & DHA Pro-Resolving Lipids

The omega-3 fatty acids EPA and DHA are precursors to specialized pro-resolving mediators (SPMs) — the molecules that actively switch off inflammation. EPA also competes with arachidonic acid for the 5-LOX and COX enzymes, shifting production away from the pro-eosinophilic mediators LTC4 and PGD2 that recruit and activate eosinophils. The most relevant SPM to EGPA is Resolvin E1 (RvE1), derived from EPA, which has been specifically shown in research to promote the resolution of eosinophilic inflammation — directly inhibiting eosinophil chemotaxis by antagonizing CCR3/eotaxin signaling and counter-regulating the IL-5 pathway in allergic airway models. Resolvin D5 has been observed to reduce IL-5 production, touching the master cytokine of the disease.

This makes omega-3s uniquely suited, in principle, to the eosinophilic core of EGPA: rather than only blocking inflammation, pro-resolving mediators help the immune system actively terminate the type 2 response. While sea moss provides only modest amounts of marine omega-3s compared to oily fish, it contributes to the overall pro-resolving lipid pool that supports the body's natural inflammation-resolution machinery.

⚙️ Zinc Immune-Regulating Mineral

Zinc is a cofactor for hundreds of metalloenzymes and a key regulator of immune balance. In the airway, zinc supports epithelial barrier integrity and metalloenzyme function, and zinc status influences the balance between effector and regulatory T-cell responses. Importantly, zinc supports FOXP3+ regulatory T-cell (Treg) function — the cells that restrain the Th2 over-activity at the heart of EGPA — helping stabilize FOXP3 expression and rebalance the Th2/Treg axis.

Zinc is also a cofactor for the matrix metalloproteinases involved in tissue remodeling; balanced MMP activity (MMP-9 in granulomas, MMP-1/MMP-13 collagenases in the heart) supports healthy remodeling rather than pathological scarring. Metallothionein, a zinc-binding protein, additionally scavenges free radicals under the oxidative stress eosinophils impose. Sea moss provides zinc as part of its broad mineral matrix, supporting normal immune regulation and tissue integrity.

🧂 Iodine Thyroid-Immune Axis

Sea moss is naturally rich in iodine, essential for thyroid hormone synthesis. The thyroid-immune axis influences metabolic and immune homeostasis, and adequate (not excessive) iodine supports normal mucosal immunity at the airway and gut surfaces — sites heavily involved in EGPA. Iodine's antimicrobial role at mucosal barriers complements the upper-airway and sinus health that is so often disrupted in EGPA. Because sea moss iodine content is high and concentrated, this is a nutrient where moderation matters — particularly for anyone with thyroid disease, which should always be discussed with your physician.

Putting It Together: A Nutritional-Support Framework

No food, supplement or sea vegetable treats, cures or prevents EGPA. The disease requires expert immunosuppression and biologic therapy. What sea moss can reasonably offer is nutritional support for the systems EGPA stresses most:

Antioxidant defense — selenium fuels the GPx enzymes that counter eosinophil-peroxidase-driven oxidative stress, including in cardiac tissue.
Normal inflammatory balance — fucoidan's interaction with NF-κB, IL-5, IL-6, complement and TGF-β1/SMAD pathways supports the body's own regulation of type 2 and vasculitic inflammation.
Inflammation resolution — omega-3-derived resolvin E1 supports the active clearance of eosinophilic inflammation.
Immune regulation — zinc supports FOXP3 Treg balance and epithelial integrity; iodine supports mucosal immunity and thyroid function.
Replenishing baseline nutrition — long-term corticosteroid therapy depletes potassium, magnesium and calcium and stresses antioxidant systems; sea moss's trace minerals help fill nutritional gaps.

Used as a daily nutritional foundation alongside — never instead of — your rheumatologist's and cardiologist's care plan, sea moss can be one supportive piece of a whole-person approach to living well with EGPA.

Frequently Asked Questions

Can sea moss treat or cure EGPA / Churg-Strauss syndrome?

No. EGPA is a serious ANCA-associated vasculitis that requires medical treatment with corticosteroids, biologics like mepolizumab, and immunosuppressants under a rheumatologist's care. Sea moss is a nutrient-dense food that supports normal immune function and antioxidant defense — it cannot lower eosinophil counts, neutralize IL-5, or reduce ANCA titers, and it should never replace prescribed therapy.

How might the nutrients in sea moss relate to eosinophilic inflammation?

Several sea moss nutrients touch pathways relevant to eosinophil biology in laboratory research: fucoidan has been studied for modulating IL-5, IL-6, eotaxin-3 and NF-κB signaling; selenium fuels glutathione peroxidase enzymes that counter the oxidative stress eosinophils generate; and omega-3-derived resolvin E1 supports the resolution of eosinophilic inflammation by inhibiting eosinophil chemotaxis. These are mechanisms of nutritional support, not disease treatment.

Is the iodine in sea moss safe if I have EGPA-related asthma or thyroid concerns?

Sea moss is naturally high in iodine, and iodine intake should be moderate. If you have any thyroid condition, are on certain medications, or have other health concerns, talk to your physician before adding sea moss — appropriate iodine intake supports thyroid and mucosal immune function, but excess can be problematic. Your care team can advise on the right amount for you.

Why is selenium emphasized for cardiac EGPA specifically?

Cardiac involvement is the leading cause of EGPA mortality and is driven largely by eosinophil granule proteins and eosinophil-peroxidase-derived oxidants (hypobromous acid) damaging the heart. Selenium is the essential cofactor for glutathione peroxidase antioxidant enzymes and for cardiac selenoproteins, so adequate selenium status supports the body's normal antioxidant defenses. This is supportive nutrition only — cardiac EGPA is a medical emergency requiring immediate specialist treatment.

Can I take sea moss alongside mepolizumab, prednisone or other EGPA medications?

Many people use nutrient-dense foods like sea moss alongside their prescribed therapy, but you should always clear any new supplement with your rheumatologist and pharmacist first. Most importantly, never stop or reduce prednisone because you started sea moss — doing so can trigger a dangerous flare. Sea moss fucoidan has mild antiplatelet and complement-modulating activity, and its iodine matters for thyroid health, so bring the actual product to your appointments before combining it with mepolizumab, benralizumab, cyclophosphamide or rituximab.

What is the difference between ANCA-positive and ANCA-negative EGPA?

About 40% of EGPA patients carry MPO-ANCA (p-ANCA) antibodies and tend toward a more vasculitic phenotype with higher rates of kidney involvement and mononeuritis multiplex, driven partly by neutrophil NETosis and complement C5a. The roughly 60% who are ANCA-negative tend toward eosinophil-driven tissue damage with more frequent — and more dangerous — cardiac involvement. The distinction guides treatment intensity and helps explain why antioxidant-focused nutritional support is conceptually most relevant in the eosinophilic, ANCA-negative subset.

Nourish Your Body with Trace Minerals

Holistic Vitalis wildcrafted sea moss delivers selenium, zinc, iodine and marine fucoidan in their natural, food-based form — a daily nutritional foundation that supports your immune balance and antioxidant defenses while you focus on living well.

Shop Sea Moss Now Free shipping on orders over $75 · Wildcrafted & nutrient-dense

Sea Moss Gels